Endocrine-Disrupting Chemicals Exposure Elimination Act of 2011

S. 847, Safe Chemicals Act of 2011, Section 30. Reduction of Animal-Based Testing. H.R. 2521 Endocrine Disrupting Chemicals Exposure Elimination Act of 2011, Title I, Research on Endocrine-Disrupting Chemicals S.1361 Endocrine Disrupting Chemicals Exposure Elimination Act of 2011, Title I, Research on Endocrine-Disrupting Chemicals

Client expense: $14,658 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R.4395, the Cosmetic Safety Amendments Act of 2012 The Breast Cancer Fund opposes this legislation as it would further weaken the FDAs ability to regulate the safety of cosmetics. H.R. 4262, the Cosmetics Safety Enhancement Act of 2012 The Breast Cancer Fund opposes this legislation as it is not strong enough to effectively regulate the safety of cosmetics. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. H.R. 3067: Accelerating the End of Breast Cancer Act of 2011. The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner. S. 3237, the Accelerating the End of Breast Cancer Act of 2012. The Breast Cancer Fund supports this legislation as it would increase focus on research to prevent, treat, and end breast cancer. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program, opposing appropriations riders limiting the work of the National Toxicology Program's Report on Carcinogens, and increasing support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Fiscal Year 2012 Appropriations for National Institutes of Health Preservation of Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2011 (H.R. 2020/S. 1096) Endocrine Disrupter Screening Enhancement Act of 2011 (HR 533) Endocrine-Disrupting Chemicals Exposure Elimination Act of 2011 (HR 2521/S.1361) Medicare Physician Payment Reform Funding for the National Diabetes Prevention Program (NDPP)

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 901, Chemical Facility Anti-Terrorism Security Authorization Act of 2011 H.R. 908, Full Implementation of the Chemical Facility Antiterrorism Security Act of 2011 H.R. 916, Continuing Chemical Facilities Antiterrorism Security Act of 2011 H.R. 6083, Federal Agriculture REform and Risk Management Act of 2012 H.R. 4965, To Preserve Existing Rights and Responsibilities with Respect to Waters of the United States, and for other purposes H.R. 910, Energy Tax Prevention Act of 2011 H.R. 1363, Further Additional Contiuing Appropriations Amendments, 2011 HJ Res 44, Futher Continuing Appropriations Amendments of 2011 HJ 48, Additional Continuing Appropriations Amendments of 2011 H Con. Res 34, FY 2012 Budget Resolution H.R. 1, Full Year Continuing Appropriations, 2011 H.R. 2112, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2012 H.R. 2584, Department of Interior, Environment, and Related Agencies Appropriations, 2012 H.R. 2018, Clean Water Cooperative Federalism Act H.R. 872, Reducing Regulatory Burdens Act of 2011 H.R. 553, Endocrine Disruptor Screening Enhacement Act of 2011 H.R. 2521, Endocrine-Disrupting Chemicals Exposure Elimination Act of 2011 H.R. 2596, CJS, Commerce, Justice, Science and Related Agencies Appropriations Act, 2012 H.R. 6083, Federal Agriculture Reform and Risk Management Act of 2012 S. 718, A bill to amend the Federal Insecticide, Fungicide, and Rodenticide Act to improve the use of certain registered pesticides S. 473, Contiuing Chemical Facilities Antiterrorism Security Act of 2011 S. 3240, Agriculture Reform, Food, and Jobs Act of 2012 S. 847, A bill to amend the Toxic Substances Control Act to ensure that risks from chemicals are adequately understood and managed, and for other purposes S. 482, Energy Tax Prevention Act of 2011 S. 1361, Endocrine-Disrupting Chemicals Exposure Elimination Act of 2011 S. 875, Drinking Water Right to Know Act S. 76, Strengthening Protections for Children and Communities from Disease Clusters Act S. 2245, Preserving the Waters of the United States Act S. 3605, Restoring Effective Environmental Protection Act S. 3552, Pesticide Registration Improvement Extension Act of 2012

S. 847, Safe Chemicals Act of 2011, Section 30. Reduction of Animal-Based Testing. H.R. 2521 Endocrine Disrupting Chemicals Exposure Elimination Act of 2011, Title I, Research on Endocrine-Disrupting Chemicals S.1361 Endocrine Disrupting Chemicals Exposure Elimination Act of 2011, Title I, Research on Endocrine-Disrupting Chemicals

Client expense: $9,864 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE

H.R. 901, Chemical Facility Anti-Terrorism Security Authorization Act of 2011 H.R. 908, Full Implementation of the Chemical Facility Antiterrorism Security Act of 2011 H.R. 916, Continuing Chemical Facilities Antiterrorism Security Act of 2011 H.R. 6083, Federal Agriculture Reform and Risk Management Act of 2012 H.R.4965, To Preserve Existing Rights and Responsibilities with Respect to Waters of the United States, and for other purposes H.R. 910, Energy Tax Prevention Act of 2011 H.R. 1363, Further Additional Continuing Appropriations Amendments, 2011 HJ Res 44, Further Continuing Appropriations Amendments, 2011 HJ 48, Additional Continuing Appropriations Amendments of 2011 H Con. Res 34, FY 2012 Budget Resolution H.R. 1, Full Year Continuing Appropriations, 2011 H.R. 2112, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2012 H.R. 2584, Department of Interior, Environment, and Related Agencies Appropriations, 2012 H.R. 2018, Clean Water Cooperative Federalism Act H.R. 872, Reducing Regulatory Burdens Act of 2011 H.R. 553, Endocrine Disruptor Screening Enhancement Act of 2011 H.R. 2521, Endocrine-Disrupting Chemicals Exposure Elimination Act of 2011 H.R. 2596, CJS, Commerce, Justice, Science and Related Agencies Appropriations Act, 2012 S. 718, A bill to amend the Federal Insecticide, Fungicide, and Rodenticide Act to improve the use of certain registered pesticides S. 473, Continuing Chemical Facilities Antiterrorism Security Act of 2011 S. 3240, Agriculture Reform, Food, and Jobs Act of 2012 S. 847, A bill to amend the Toxic Substances Control Act to ensure that risks from chemicals are adequately understood and managed, and for other purposes S. 482, Energy Tax Prevention Act of 2011 S. 1361, Endocrine-Disrupting Chemicals Exposure Elimination Act of 2011 S. 875, Drinking Water Right to Know Act S. 76, Strengthening Protections for Children and Communities from Disease Clusters Act S. 2245, Preserving the Waters of the United States Act

H.R. 2020/S. 1096 Preservation of Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2011 Fiscal Year 2012 Appropriations for National Institutes of Health H.R. 533 Endocrine Disruptor Screening Enhancement Act of 2011 H.R. 2521/S. 1361 Endocrine Disrupting Chemicals Exposure Elimination Act of 2011 Medicare Physician Payment Reform Funding for National Diabetes Prevention Program (NDPP)

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R.4395, the Cosmetic Safety Amendments Act of 2012 The Breast Cancer Fund opposes this legislation as it would further weaken the FDAs ability to regulate the safety of cosmetics. H.R. 4262, the Cosmetics Safety Enhancement Act of 2012 The Breast Cancer Fund opposes this legislation as it is not strong enough to effectively regulate the safety of cosmetics. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. H.R. 3067: Accelerating the End of Breast Cancer Act of 2011. The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner. S. 3237, the Accelerating the End of Breast Cancer Act of 2012. The Breast Cancer Fund supports this legislation as it would increase focus on research to prevent, treat, and end breast cancer. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

S. 847, Safe Chemicals Act of 2011, Section 30. Reduction of Animal-Based Testing. H.R. 2521 Endocrine Disrupting Chemicals Exposure Elimination Act of 2011, Title I, Research on Endocrine-Disrupting Chemicals S.1361 Endocrine Disrupting Chemicals Exposure Elimination Act of 2011, Title I, Research on Endocrine-Disrupting Chemicals

Client expense: $12,501 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE

H.R. 901, Chemical Facility Anti-Terrorism Security Authorization Act of 2011 H.R. 908, Full Implementation of the Chemical Facility Antiterrorism Security Act of 2011 H.R. 916, Continuing Chemical Facilities Antiterrorism Security Act of 2011 S. 473, Continuing Chemical Facilities Antiterrorism Security Act of 2011 S. 847, A bill to amend the Toxic Substances Control Act to ensure that risks from chemicals are adequately understood and managed, and for other purposes H.R. 910, Energy Tax Prevention Act of 2011 S. 482, Energy Tax Prevention Act of 2011 H.R. 1363, Further Additional Continuing Appropriations Amendments, 2011 HJ Res 44, Further Continuing Appropriations Amendments, 2011 HJ Res 48, Additional Continuing Appropriations Amendments of 2011 H Con. Res 34, FY 2012 Budget Resolution H.R. 1, Full Year Continuing Appropriations, 2011 H.R. 2112, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2012 H.R. 2584, Department of Interior, Enviornment, and Related Agencies Appropriations, 2012 H.R. 2018, Clean Water Cooperative Federalism Act H.R. 872, Reducing Regulatory Burdens Act of 2011 S. 718, A bill to amend the Federal Insecticide, Fungicide, and Rodenticide Act to improve the use of certain registered pesticides H.R. 553, Endocrine Disruptor Screening Enhancement Act of 2011 H.R. 2521, Endocrine-Disrupting Chemicals Exposure Elimination Act of 2011 S. 1361, Endocrine-Disrupting Chemicals Exposure Elimination Act of 2011 S. 875, Drinking Water Right to Know Act S. 76, Strengthening Protections for Children and Communities from Disease Clusters Act H.R. 2596, CJS, Commerce, Justice, Science and Related Agencies Appropriations Act, 2012 S. 2245, Preserve the Waters of the United States Act

Client expense: $524,687 · Firm income: Not reported

Fiscal Year 2012 Appropriations for National Institutes of Health H.R. 2020/ S. 1096 Preservation of Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2011 H.R. 533 Endocrine Disruptor Screening Enhancement Act of 2011 H.R. 2521/S. 1361 Endocrine Disrupting Chemicals Exposure Elimination Act of 2011 Medicare Physician Payment Reform Funding for National Diabetes Prevention Program (NDPP)

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. H.R. 3067: Accelerating the End of Breast Cancer Act of 2011. The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

S. 847, Safe Chemicals Act of 2011, Section 30. Reduction of Animal-Based Testing. H.R. 2521 Endocrine Disrupting Chemicals Exposure Elimination Act of 2011, Title I, Research on Endocrine-Disrupting Chemicals S.1361 Endocrine Disrupting Chemicals Exposure Elimination Act of 2011, Title I, Research on Endocrine-Disrupting Chemicals

Client expense: $14,200 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE

Fiscal Year 2012 Appropriations for National Institutes of Health H.R. 2020/ S. 1096 Preservation of Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2011 H.R. 533 Endocrine Disruptor Screening Enhancement Act of 2011 H.R. 2521/S. 1361 Endocrine Disrupting Chemicals Exposure Elimination Act of 2011 Medicare Physician Payment Reform Funding for National Diabetes Prevention Program (NDPP)

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. H.R. 3067: Accelerating the End of Breast Cancer Act of 2011. The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

H.R. 901, Chemical Facility Anti-Terrorism Security Authorization Act of 2011 H.R. 908, Full Implementation of the Chemical Facility Antiterrorism Security Act of 2011 H.R. 916, Continuing Chemical Facilities Antiterrorism Security Act of 2011 S. 473, Continuing Chemical Facilities Antiterrorism Security Act of 2011 S. 847, A bill to amend the Toxic Substances Control Act to ensure that risks from chemicals are adequately understood and managed, and for other purposes H.R. 910, Energy Tax Prevention Act of 2011 S. 482, Energy Tax Prevention Act of 2011 H.R. 1363, Further Additional Continuing Appropriations Amendments, 2011 HJ Res 44, Further Continuing Appropriations Amendments, 2011 HJ Res 48, Additional Continuing Appropriations Amendments of 2011 H Con. Res 34, FYI 2012 Budget Resolution H.R. 1, Full Year Continuing Appropriations, 2011 H.R. 2112, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2012 H.R. 2584, Department of Interior, Environment, and Related Agencies Appropriations, 2012 H.R. 2018, Clean Water Cooperative Federalism Act H.R. 872, Reducing Regulatory Burdens Act of 2011 S. 718, A bill to amend the Federal Insecticide, Fungicide, and Rodenticide Act to improve the use of certain registered pesticides H.R. 553, Endocrine Disruptor Screening Enhancement Act of 2011 H.R. 2521, Endocrine-Disrupting Chemicals Exposure Elimination Act of 2011 S. 1361, Endocrine-Disrupting Chemicals Exposure Elimination Act of 2011 S. 875, Drinking Water Right to Know Act S. 76, Strengthening Protections for Children and Communities from Disease Clusters Act H.R. 2596 CJS, Commerce, Justice, Science and Related Agencies Appropriations Act, 2012

Client expense: $899,469 · Firm income: Not reported

S. 847, Safe Chemicals Act of 2011, Section 30. Reduction of Animal-Based Testing. H.R. 2521 Endocrine Disrupting Chemicals Exposure Elimination Act of 2011, Title I, Research on Endocrine-Disrupting Chemicals S.1361 Endocrine Disrupting Chemicals Exposure Elimination Act of 2011, Title I, Research on Endocrine-Disrupting Chemicals

Client expense: $17,200 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

S.1445, Raechel and Jacqueline Houck Safe Rental Car Act of 2011 H.R.2521, Endocrine-Disrupting Chemicals Exposure Elimination Act of 2011 H.R.2715, To provide the Consumer Product Safety Commission with greater authority and discretion in enforcing the consumer product safety laws, and for other purposes S.1449, Mariah's Act (issues related to distracted driving, motor vehicle safety, transparency and accessibility) S.1606, Regulatory Accountability Act of 2011 (issues related to the impact of applying cost/benefit analysis to consumer protection regulations) S.1223, Location Privacy Protection Act of 2011 S.1361, Endocrine-Disrupting Chemicals Exposure Elimination Act of 2011 Issues related to FDA implementation of Food Safety Modernization Act (P.L. 111-353) Issues related to implementation of the Consumer Product Safety Modernization Act (P.L. 110-314) Issues related to auto safety, car rental safety, and distracted driving Issues related to CPSC third party testing, complaints database, and FY 2012 funding Issues related to the National Highway Traffic Safety Administration appropriations Issues related to glass bakeware product safety

Client expense: $50,000 · Firm income: Not reported

H.R. 901, Chemical Facility Anti-Terrorism Security Authorization Act of 2011 H.R. 908, Full Implementation of the Chemical Facility Anti-Terrorism Standards Act H.R. 916, Continuing Chemical Facilities Antiterrorism Security Act of 2011 S. 473, Continuing Chemical Facilities Antiterrorism Security Act of 2011 S. 847, A bill to amend the Tocis Substances Control Act to ensure that risks from chemicals are adequately understood and managed, and for other purposes H.R. 910, Energy Tax Prevention Act of 2011 S. 482, Energy Tax Prevention Act of 2011 H.R. 1363, Further Additional Continuing Appropriations Amendments, 2011 HJ Res 44, Further Continuing Appropriations Amendments, 2011 HJ Res 48, Additional Continuing Appropriations Amendments of 2011 H Con. res 34, FYI 2012 Budget Resolution H.R. 1, Full Year Continuing Appropriations, 2011 H.R. 2112, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2012 H.R. Department of the Interior, Environment, and Related Agencies Appropriations Act, 2012 H.R. 2018, Clean Water Cooperative Federalism Act H.R. 872, Reducing Regulatory Burdens Act of 2011 S. 718, A bill to amend the Federal Insecticide, Fungicide, and Rodenticide Act to improve the use of certain registered pesticides H.R. 553, Endocrine Disruptor Screening Enahancement Act of 2011 H.R. 2521, Endocrine-Disrupting Chemicals Exposure Elimination Act of 2011 S. 1361, Endocrine-Disrupting Chemicals Exposure Elimination Act of 2011 S. 875, Drinking Water Right to Know Act S. 76, Strengthening Protections for Children and Communities From Disease Clusters Act

Client expense: $494,457 · Firm income: Not reported

S. 847, Safe Chemicals Act of 2011, Section 30. Reduction of Animal-Based Testing. H.R. 2521 Endocrine Disrupting Chemicals Exposure Elimination Act of 2011, Title I, Research on Endocrine-Disrupting Chemicals S.1361 Endocrine Disrupting Chemicals Exposure Elimination Act of 2011, Title I, Research on Endocrine-Disrupting Chemicals

Client expense: $10,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.